FrancophonIA/ELRC3.0 huggingface dataset:
English: Telavancin is a low clearance active substance with a mean (SD) CL of 13.1 (2.0) ml/hr/kg in subjects with normal renal function, corresponding to a total CL of approximately 1 l/hr in a 75 kg subject.
Croatian: Telavancin je djelatna tvar s niskim klirensom sa srednjom vrijednosti (SD) CL od 13,1 (2,0) ml/hr/kg kod pojedinaca s normalnom bubrežnom funkcijom što odgovara ukupnom CL od približno 1 l/hr za osobu težine 75 kg.
English: Patients with severe renal impairment, i.e. creatinine clearance (CrCl) <30 ml/min, including patients undergoing haemodialysis (see section 4.4).
Croatian: Bolesnici s teškim oštećenjem funkcije bubrega, odnosno s klirensom kreatinina (CrCl) < 30 ml/min uključujući bolesnike na hemodijalizi (vidjeti dio 4.4).
English: After reconstitution, each ml contains 15 mg of telavancin.
Croatian: Nakon rekonstitucije svaki ml sadrži 15 mg telavancina.
English: If you are given more VIBATIV than you should receive, the chance of experiencing the following side effects increases: disturbed taste, nausea (feeling sick), vomiting, reactions at the site of the infusion, headache, rash, skin flushing of the upper body.
Croatian: Ako ste dobili više lijeka VIBATIV nego što ste trebali primiti, povećava se mogućnost pojave sljedećih nuspojava: poremećaja okusa, mučnine, povraćanja, reakcije na mjestu primjene infuzije,
English: A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with telavancin should be made taking into account the benefit of breastfeeding to the child and the benefit of telavancin therapy to the woman.
Croatian: Odluka o nastavku/prekidu dojenja odnosno nastavku/prekidu terapije treba se donijeti uzimajući u obzir prednosti dojenja za dijete i prednosti liječenja
English: The pregnancy status of women of childbearing potential has to be established prior to dosing with telavancin.
Croatian: Trudnoća žene u reprodukcijskoj dobi mora se utvrditi prije propisivanja doze telavancina.
English: Acute renal failure (see section 4.4).
Croatian: Akutno zatajenje bubrega (vidjeti dio 4.4).
English: Antibiotic-associated colitis and pseudomembranous colitis
Croatian: Kolitis vezan uz primjenu antibiotika i pseudomembranozni kolitis
English: Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system
Croatian: Od zdravstvenih radnika se traži da prijave svaku sumnju na nuspojavu lijeka putem nacionalnog sustava prijave nuspojava navedenog u Dodatku V.
English: Therefore, no dose adjustment is necessary when administering telavancin to subjects with mild or moderate degrees of hepatic impairment.
Croatian: Zbog toga nije potrebno prilagođavanje doze kada se telavancin primjenjuje kod osoba s blagim ili umjerenim oštećenjem funkcije jetre.
English: In the clinical studies, patients with pre existing acute renal failure receiving telavancin had an increased risk of mortality.
Croatian: Klinička su ispitivanja pokazala da je kod bolesnika s već postojećim akutnim zatajenjem bubrega koji primaju telavancin veći rizik od smrtnosti.
English: There is no known cross-resistance between telavancin and other non-glycopeptide classes of antibiotics.
Croatian: Nema poznate križne rezistencije između telavancina i drugih neglikopetidnih
English: At a dose of 10 mg/kg, mean Vss averaged between 133 (SD 24) ml/kg after multiple dosing, corresponding to a value of approximately 10 l for a 75 kg person.
Croatian: Vss je bila između 133 (SD 24) ml/kg nakon višekratnog doziranja što odgovara vrijednosti od približno 10 l za osobu težine 75 kg.
English: It is not known if telavancin passes into breast milk in humans.
Croatian: Nije poznato prelazi li telavancin u majčino mlijeko.
English: Ask your doctor for advice before
Croatian: Potražite savjet liječnika prije dojenja djeteta.
English: The most commonly reported related adverse reactions (occurring in >1% of patients) were: fungal infection, insomnia, dysgeusia, headache, dizziness, nausea, constipation, diarrhoea, vomiting, alanine aminotransferase increased, aspartate aminotransferase increased, pruritus, rash, renal failure acute, blood creatinine increased, urine abnormality (foamy urine), fatigue and chills.
Croatian: Najčešće prijavljene nuspojave (koje su se pojavile na >1% bolesnika) bile su: gljivična infekcija, nesanica, disgeuzija, glavobolja, omaglica, mučnina, konstipacija, dijareja, povraćanje, povećanje alanin aminotransferaze, povećanje aspartat aminotransferaze, svrbež, osip, akutno zatajenje bubrega, povećanje razine kreatinina u krvi, promjena mokraće (pjenušava mokraća), umor i zimica.
English: For storage conditions of the reconstituted or diluted medicinal product, see section 6.3.
Croatian: Uvjete čuvanja nakon rekonstitucije ili razrjeđivanja lijeka vidjeti u dijelu 6.3.
English: • That the benefit risk balance for the Complicated Skin and Soft Tissue Infections indication was assessed as negative by the Committee for Medicinal Products for Human Use (CHMP), therefore Vibativ should not be used in this or other indications not approved.
Croatian: • da je Povjerenstvo za humane lijekove (CHMP) procijenilo omjer rizika i koristi za indikaciju kompliciranih infekcija kože i mekog tkiva kao negativan te se zbog toga
English: Foaming may occur during reconstitution but will dissipate upon standing.
Croatian: Tijekom rekonstitucije može se pojaviti pjena koja nestaje dok otopina stoji.
English: Powder for concentrate for solution for infusion A white to pale pink, whole or fragmented cake
Croatian: Bijeli do blijedo ružičasti, kompaktni ili razlomljeni prašak
English: Common: may affect up to 1 in 10 people kidney disorder, abnormal kidney function tests, foamy urine
Croatian: Često: može se javiti u manje od 1 na 10 osoba povećana razina jetrenih enzima u krvi oštećenje bubrega, abnormalni rezultati pretraga funkcije bubrega, pjenušava mokraća
English: 1 vial of 30 ml with 250 mg telavancin 1 vial of 50 ml with 750 mg telavancin
Croatian: 1 bočica od 30 ml s 250 mg telavancina 1 bočica od 50 ml s 750 mg telavancina
English: After reconstitution, each ml of concentrated solution contains 15 mg of telavancin.
Croatian: Nakon rekonstitucije, svaki ml koncentrirane otopine sadrži 15 mg telavancina.
English: Treatment was discontinued due to adverse reactions in 5.0% of patients who received telavancin.
Croatian: 5,0% bolesnika koji su primali telavancin prekinulo je liječenje zbog nuspojava.
English: QUALITATIVE AND QUANTITATIVE COMPOSITION VIBATIV 250 mg powder for concentrate for solution for infusion Each vial contains 250 mg telavancin (as hydrochloride).
Croatian: 2. KVALITATIVNI I KVANTITATIVNI SASTAV VIBATIV 250 mg prašak za koncentrat za otopinu za infuziju Svaka bočica sadrži 250 mg telavancina (u obliku telavancinklorida).
English: In addition, caution is warranted when using telavancin to treat patients with congenital long QT syndrome, known prolongation of the QTc interval, uncompensated heart failure,
Croatian: Osim toga oprez je potreban kada se telavancin upotrebljava za liječenje bolesnika s urođenim sindromom produljenog QT intervala, poznatim produljenim QTc intervalom, nekompenziranim zatajenjem srca ili teškom hipertrofijom lijeve klijetke.
English: Paediatric patients The pharmacokinetics of telavancin in patients below 18 years of age have not been established (see
Croatian: Farmakokinetika telavancina kod bolesnika mlađih od 18 godina još nije ustanovljena (vidjeti dio 4.2).
English: If an allergic reaction to telavancin occurs, discontinue treatment and institute
Croatian: Ako dođe do alergijske reakcije na telavancin prekinite liječenje i uvedite
English: Important information about some of the ingredients of VIBATIV This medicine contains less than 1 mmol sodium (23 mg) per vial, i.e. essentially ‘sodium-free'.
Croatian: Ovaj lijek sadrži manje od 1 mmol natrija (23 mg) po bočici, tj. sadrži zanemarive količine natrija.
English: • That Vibativ has a risk of nephrotoxicity including increased risk of mortality in patients with pre existing acute renal failure and is therefore contraindicated in patients with pre-existing acute renal failure and in patients with creatinine clearance < 30ml/min, including patients undergoing haemodialysis.
Croatian: • da kod primjene lijeka Vibativ postoji rizik od nefrotoksičnosti koji uključuje povećani rizik od smrti u bolesnika s već postojećim akutnim zatajenjem bubrega te je stoga kontraindiciran kod bolesnika s već postojećim akutnim zatajenjem bubrega i bolesnika kojima je klirens kreatinina
English: While antibiotics including VIBATIV fight certain bacteria, other bacteria and fungi may continue to grow.
Croatian: Zvonjenje u ušima i gluhoća predstavljaju moguće nuspojave. dok antibiotici među kojima je VIBATIV djeluju na određene vrste bakterija, druge bakterije i gljivice nastavljaju rast.
English: MANUFACTURER RESPONSIBLE FOR BATCH RELEASE CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND
Croatian: UVJETI ILI OGRANIČENJA VEZANI UZ OPSKRBU I
English: CARTON AND VIAL
Croatian: KUTIJA I BOČICA
English: VIBATIV 750 mg powder for concentrate for solution for infusion Each vial contains 750 mg telavancin (as hydrochloride).
Croatian: VIBATIV 750 mg prašak za koncentrat za otopinu za infuziju Svaka bočica sadrži 750 mg telavancina (u obliku telavancinklorida).
English: Studies in animals have shown reproductive toxicity
Croatian: Ispitivanja na životinjama pokazala su reproduktivnu toksičnost (vidjeti dio 5.3).
English: Caution should be used when prescribing VIBATIV to patients receiving concomitant nephrotoxic medicines, those with pre existing renal disease or with co-morbidity known to predispose to kidney dysfunction (e.g. diabetes mellitus, congestive heart failure, hypertension).
Croatian: Ostali čimbenici koji mogu povećati rizik od nefrotoksičnosti Moraju se poduzeti mjere opreza prilikom propisivanja lijeka VIBATIV bolesnicima koji istodobno primaju nefrotoksične lijekove, onima s postojećom bolesti bubrega ili s komorbiditetom za kojeg se zna da može predisponirati poremećaj funkcije bubrega (npr. šećerna bolest, kongestivno srčano
English: Initial dose and dosage adjustments during treatment should be made based on calculated or measured creatinine clearance according to the dosing regimen in section 4.2.
Croatian: Početna doza i prilagođavanje doze tijekom liječenja trebaju se temeljiti na izračunatom ili izmjerenom klirensu kreatinina u skladu s režimom doziranja navedenim u dijelu 4.2. Ako dođe do značajnog smanjenja bubrežne funkcije tijekom liječenja treba se procjeniti korist nastavka primjene
English: The use in patients with acute renal failure or creatinine clearance (CrCl) <30 ml/min including patients undergoing haemodialysis is contraindicated (see section 4.3).
Croatian: Primjena je kontraindicirana kod bolesnika s akutnim zatajenjem bubrega ili kod onih kod kojih je klirens kreatinina (CrCl) <30 ml/min uključujući i bolesnike na hemodijalizi (vidjeti dio 4.3).
English: VIBATIV 250 mg powder for concentrate for solution for infusion 1 vial of 30 ml with 250 mg telavancin
Croatian: VIBATIV 250 mg prašak za koncentrat za otopinu za infuziju 1 bočica od 30 ml s 250 mg telavancina
English: Body mass index (BMI) at baseline was found to influence telavancin pharmacokinetics in the population pharmacokinetic analysis in healthy (without infection) adult subjects.
Croatian: Body Mass Index, BMI) utječu na farmakokinetiku telavancina.
English: Telavancin may interfere with some laboratory tests that measure how well your blood is clotting.
Croatian: Može doći do interakcije telavancina s nekim laboratorijskim pretragama koja mjere vrijeme zgušavanja krvi.
English: VIBATIV is indicated for the treatment of adults with nosocomial pneumonia (NP) including ventilator associated pneumonia, known or suspected to be caused by methicillin-resistant
Croatian: VIBATIV je indiciran za liječenje odraslih osoba s bolničkom upalom pluća koja uključuje upalu pluća povezanu s mehaničkom ventilacijom za koju je utvrđeno ili se sumnja da je uzrokuje meticilin-rezistentan Staphylococcus aureus (MRSA).
English: nausea constipation, diarrhoea, vomiting abdominal pain, dry mouth, dyspepsia, flatulence, hypoaesthesia alanine aminotransferase increased, aspartate aminotransferase erythema, face oedema, hyperhidrosis, urticaria Musculoskeletal and connective tissue disorders arthralgia, back pain, muscle cramp, myalgia renal failure acute, blood creatinine increased, foamy urine (lower blood urea increased, dysuria, haematuria, microalbuminuria, oliguria, pollakiuria, renal impairment, urine odour abnormal General disorders and administration site conditions asthenia, infusion site reactions, malaise, non-cardiac chest pain, peripheral oedema, pain, pyrexia, Red Man syndrome international normalised ratio increased * Based on post-marketing reports.
Croatian: Poremećaji kože i potkožnog tkiva eritem, edem lica, hiperhidroza, urtikarija Poremećaji mišićno-koštanog sustava i vezivnog tkiva artralgija, bol u leđima, grčevi mišića, mijalagija Poremećaji bubrega i mokraćnog sustava akutno zatajenje bubrega, povećanje razine kreatinina u krvi, pjenušava mokraća (pojam niže razine - LLT), povećana razina ureje u krvi, dizurija, hematurija, mikroalbuminurija, oligurija, polakizurija, oštećenje funkcije bubrega, neuobičajeni miris mokraće Opći poremećaji i reakcije na mjestu primjene astenija, reakcije na mjestu infuzije, malaksalost, nekardijalna bol u prsištu, periferni edem, bol, vrućica, sindrom crvenog čovjeka povećani internacionalni normalizirani omjer
English: Therefore, the use of telavancin in patients with pre-existing acute renal failure and in patients with severe renal impairment is contraindicated (see
Croatian: Zbog toga je primjena telavancina kod bolesnika s već postojećim akutnim zatajenjem bubrega i kod bolesnika s teškim oštećenjem funkcije bubrega kontraindicirana (vidjeti dio 4.3).
English: Caution should be exercised when prescribing telavancin to patients with a prior history of hypersensitivity reaction to vancomycin.
Croatian: Moraju se poduzeti mjere opreza prilikom propisivanja telavancina bolesnicima preosjetljivim na vankomicin.
English: flushing, hypertension, hypotension, phlebitis Respiratory, thoracic and mediastinal disorders Uncommon:
Croatian: crvenilo uz osjećaj vrućine, hipertenzija, hipotenzija, flebitis Poremećaji dišnog sustava, prsišta i sredoprsja Manje često:
English: Also, the pharmacokinetics of aztreonam or piperacillin tazobactam were not altered by telavancin.
Croatian: Također, telavancin nije utjecao na farmakokinetiku aztreonama ili piperacilina/tazobaktama.
English: Appropriate infusion solutions include: dextrose 50 mg/ml (5%) solution for injection, sodium chloride 9 mg/ml (0.9%) solution for injection or lactated Ringer's solution for injection.
Croatian: Odgovarajuća otopina za infuziju uključuje: otopinu glukoze za injekciju koncentracije 50 mg/ml (5%), otopinu natrijevog klorida za injekciju koncentracije 9 mg/ml (0,9%) ili Ringerovu otopinu s laktatom za injekciju.
English: clostridium colitis, urinary tract infection anaemia, leukopenia, thrombocythaemia, thrombocytopenia, eosinophil count increased, neutrophil count increased decreased appetite, hyperglycaemia, hyperkalaemia, hypoglycaemia, hypokalaemia, hypomagnesaemia agitation, anxiety, confusional state, depression ageusia, migraine, paraesthesia, parosmia, somnolence, tremor
Croatian: Poremećaji metabolizma i prehrane smanjenje apetita, hiperglikemija, hiperkalemija, hipoglikemija, hipokalemija, hipomagnezijemija agitacija, anksioznost, konfuzno stanje, depresija ageuzija, migrena, parestezija, parosmija, izrazita pospanost, tremor iritacija očiju, zamućeni vid
English: There is no human experience with telavancin.
Croatian: Nema iskustava o upotrebi telavancina u ljudi.
English: Uncommon: may affect up to 1 in 100 people intestinal bacterial infection; urinary tract infection anaemia, changes in white blood cell counts; changes in blood platelet counts decreased appetite; changes in blood levels of glucose; changes in blood levels of potassium and restlessness; anxiety; confusion; depression loss of taste, migraine, abnormal touch sensation, smell disturbance, sleepiness, trembling chest pain; heart failure; abnormal heart rhythm or heart beat flushing; high or low blood pressure; inflammation of a vein breathlessness, hiccups, nasal congestion, sore throat abdominal pain; dry mouth; indigestion, bloating; numbness of the mouth skin redness; swelling of face; sweating, hives joint pain; back pain; muscle cramp; muscle pain painful urination; blood in urine; low urine output, frequent urination; abnormal urine odour lack of energy; irritation at infusion site; feeling unwell; chest discomfort; accumulation of fluid in the lower legs; pain; fever; skin flushing of upper body
Croatian: iritacija očiju, zamućeni vid bol u prsnom košu, zatajenje srca, neuobičajeni srčani ritam ili otkucaji srca crvenilo uz osjećaj vrućine, visok ili nizak krvni tlak, upala vena, nedostatak zraka, štucanje, začepljenost nosa, grlobolja bol u trbuhu, suha usta, probavne tegobe, nadimanje, utrnulost usta crvenilo kože, oticanje lica, znojenje, koprivnjača bol u zglobovima, bol u leđima, grčevi mišića, bol u mišićima bolno mokrenje, krv u mokraći, slabo mokrenje, često mokrenje, neuobičajen miris mokraće pomanjkanje energije, iritacija na mjestu infuzije, loše osjećanje, neugodan osjećaj u prsnom košu, nakupljanje tekućine u donjem dijelu nogu, bol, vrućica, crvenilo uz osjećaj vrućine abnormalni rezultati pretraga zgrušavanja krvi.
English: VIBATIV 750 mg powder for concentrate for solution for infusion 1 vial of 50 ml with 750 mg telavancin
Croatian: VIBATIV 750 mg prašak za koncentrat za otopinu za infuziju 1 bočica od 50 ml sadrži750 mg telavancina
English: No evidence of increased bleeding risk has been observed in clinical trials with telavancin.
Croatian: U kliničkim ispitivanjima s telavancinom nije primijećen povećani rizik od krvarenja.
English: Reconstitution time is not more than 5 minutes for the vial containing 250 mg and not more than 10 minutes for the vial containing 750 mg.
Croatian: Vrijeme rekonstitucije nije dulje od 5 minuta za bočicu koja sadrži 250 mg i nije dulje od 10 minuta za Miješanje se nastavlja sve dok se sadržaj bočice u potpunosti ne otopi i ako vizualnom kontrolom
English: After addition of either dextrose 50 mg/ml (5%) solution for injection, or water for injections or sodium chloride 9 mg/ml (0.9%) solution for injection, the contents of the vial are mixed by swirling gently to facilitate reconstitution.
Croatian: Nakon dodavanja otopine glukoze za injekciju u koncentraciji 50 mg/ml (5%), vode za injekciju ili otopine natrijevog klorida za injekciju u koncentraciji od 9 mg/ml (0,9%), sadržaj bočice se miješa laganom vrtnjom kako bi se
English: Coagulation tests unaffected by telavancin
Croatian: Pretrage koagulacije na koje je telavancin utjecao Pretrage koagulacije na koje telavancin nije utjecao
English: if you develop diarrhoea during or shortly after your treatment, tell your doctor immediately.
Croatian: Vaš će liječnik nadzirati sve potencijalne infekcije i po potrebi ih liječiti. ako dobijete proljev tijekom ili kratko nakon liječenja, odmah o tome obavijestite liječnika.
English: Activated partial thromboplastin time
Croatian: Vrijeme zgrušavanja pune krvi (Lee-White) Aktivirano parcijalno tromboplastinsko vrijeme Agregacija trombocita ex vivo Aktivirano vrijeme zgrušavanja
English: VIBATIV 250 mg powder for concentrate for solution for infusion VIBATIV 750 mg powder for concentrate for solution for infusion
Croatian: VIBATIV 250 mg prašak za koncentrat za otopinu za infuziju VIBATIV 750 mg prašak za koncentrat za otopinu za infuziju
English: Progress on enrolment will be submitted with the PSURs.
Croatian: Napredak u uključivanju podnijet će se uz periodičko izvješće o neškodljivosti (PSUR).
English: 10 mg/kg every 24 hours 7.5 mg/kg every 24 hours *As calculated using the Cockcroft-Gault formula
Croatian: 7,5 mg/kg svakih 24 sata
English: VIBATIV 750 mg powder for concentrate for solution for infusion
Croatian: VIBATIV 750 mg prašak za koncentrat za otopinu za infuziju
English: VIBATIV 750 mg powder for concentrate for solution for infusion The contents of the vial containing 750 mg telavancin must be reconstituted with 45 ml of either dextrose 50 mg/ml (5%) solution for injection, or water for injections or sodium chloride 9 mg/ml (0.9%) solution for injection to obtain a concentration of approximately 15 mg/ml (total volume of
Croatian: VIBATIV 750 mg prašak za koncentrat za otopinu za infuziju Sadržaj bočice koja sadrži 750 mg telavancina mora se rekonstituirati s 45 ml otopine glukoze za injekciju koncentracije 50 mg/ml (5%) ili vode za injekciju ili otopine natrijevog klorida za injekciju koncentracije 9 mg/ml (0,9%) kako bi se dobila koncentracija od približno 15 mg/ml (ukupni volumen
English: VIBATIV 250 mg powder for concentrate for solution for infusion The contents of the vial containing 250 mg telavancin must be reconstituted with 15 ml of either dextrose 50 mg/ml (5%) solution for injection, or water for injections or sodium chloride 9 mg/ml (0.9%) solution for injection to obtain a concentration of approximately 15 mg/ml (total volume of approximately 17 ml).
Croatian: VIBATIV 250 mg prašak za koncentrat za otopinu za infuziju Sadržaj bočice koja sadrži 250 mg telavancina mora se rekonstituirati s 15 ml otopine glukoze za injekciju koncentracije 50 mg/ml (5%) ili vode za injekciju ili otopine natrijevog klorida za injekciju koncentracije 9 mg/ml (0,9%) kako bi se dobila koncentracija od približno 15 mg/ml (ukupni volumen je približno 17 ml).
English: VIBATIV 250 mg powder for concentrate for solution for infusion
Croatian: VIBATIV 250 mg prašak za koncentrat za otopinu za infuziju telavancin
English: Discard any unused solution.
Croatian: Neupotrijebljenu otopinu bacite.
English: The solution is to be inspected visually for particulate matter and discoloration prior to administration.
Croatian: Otopinu prije primjene treba vizualno prekontrolirati sadrži li čestice i je li promijenila boju.
English: The dilution is to be made under
Croatian: Razrjeđivanje se mora obaviti u aseptičkim uvjetima.
English: NAME OF THE MEDICINAL PRODUCT VIBATIV 250 mg powder for concentrate for solution for infusion
Croatian: BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET VIBATIV 250 mg prašak za koncentrat za otopinu za infuziju
English: Preparation of the reconstituted concentrate (VIBATIV 750 mg vial) The contents of the vial containing 750 mg telavancin must be reconstituted with 45 ml of either dextrose 50 mg/ml (5%) solution for injection, or water for injections or sodium chloride 9 mg/ml (0.9%) solution for injection to obtain a concentration of approximately 15 mg/ml (total volume of approximately 50 ml).
Croatian: Sadržaj bočice koja sadrži 750 mg telavancina mora se rekonstituirati s 45 ml otopine glukoze za injekciju koncentracije 50 mg/ml (5%) ili vode za injekciju ili otopine natrijevog klorida za injekciju koncentracije 9 mg/ml (0,9%) kako bi se dobila koncentracija od približno 15 mg/ml (ukupni volumen je približno 50 ml).
English: Vascular disorders Uncommon:
Croatian: Poremećaji imunološkog sustava
English: Gastrointestinal disorders Very common:
Croatian: Kromogeni test faktora Xa
English: VIBATIV 250 mg powder for concentrate for solution for infusion VIBATIV 750 mg powder for concentrate for solution for infusion telavancin This medicine is subject to additional monitoring.
Croatian: VIBATIV 250 mg prašak za koncentrat za otopinu za infuziju VIBATIV 750 mg prašak za koncentrat za otopinu za infuziju telavancin
English: Other factors that may increase the risk of nephrotoxicity
Croatian: • Dodatne mjere minimizacije rizika
English: If you get any side effects, talk your doctor or pharmacist.
Croatian: Ako primijetite bilo koju nuspojavu, potrebno je obavijestiti liječnika ili ljekarnika.
English: dyspnoea, hiccups, nasal congestion, pharyngolaryngeal pain
Croatian: klostridijski kolitis, infekcija mokraćnog sustava
English: Human Papillomavirus1 type 18 L1 protein2,3,4
Croatian: humani papilomavirus1 tip 18 L1 protein2,3,4
English: 3-O-desacyl-4'- monophosphoryl lipid A (MPL)
Croatian: 3-O-desacil-4'-monofosforil lipid A (MPL)3